Bayer's Stock Stands Still as a Settlement, a Biotech Deal, and a Trade Probe Cross Paths

Bayer stock flat as US judge approves class-action settlement framework, trade probe looms, and $2.45B Perfuse deal closes.

Bayer's share price has barely budged in recent weeks, but the stillness masks a flurry of developments that pull the German pharmaceutical and agrichemicals giant in opposing directions. A US judge has just confirmed the framework for a long-awaited class-action settlement, offering some legal breathing room, but a fresh trade probe into German drug pricing threatens to open a new regulatory front. At the same time, the company has quietly closed a $2.45 billion biotech bet.

The Perfuse Therapeutics acquisition, completed on 17 June, injects a Phase II intravitreal implant called PER-001 into Bayer’s ophthalmology pipeline. The upfront cost is $300 million, with milestone payments that could push the total to $2.45 billion. The implant targets glaucoma and diabetic retinopathy, two of the largest unmet needs in eye care. The deal underscores Bayer’s strategy of building specialty pharma assets beyond its core blockbusters.

Legal battles remain a constant. In February, Bayer sued Johnson & Johnson, accusing it of misleading advertising for its prostate cancer drug Erleada. Bayer claims J&J’s assertion that Erleada reduces the risk of death by 51% versus its own drug Nubeqa relies on a flawed retrospective analysis, not controlled clinical trials. A US federal judge rejected Bayer’s request for a preliminary injunction in April, and the case rumbles on. Meanwhile, the Supreme Court is expected to deliver its verdict on glyphosate liability by the end of June — a ruling that could ripple through Bayer’s balance sheet for years.

The trade probe, launched by the US Trade Representative on 18 June under Section 301, examines whether Germany’s drug pricing rules discriminate against American commerce. As the country’s largest pharmaceutical manufacturer, Bayer sits squarely in the crosshairs, adding a geopolitical overlay to an already crowded risk calendar. Earlier in the week, Israeli airstrikes in Lebanon also stalled US-Iran talks, sending investors into safe havens — gold and US Treasuries gained while blue-chip equities sagged. On Monday, Bayer shares oscillated in a tight band between €37.80 and €37.84, reflecting the market’s wait-and-see posture.

Technically, the stock closed last Friday at €37.81, up 4.36% over the prior seven days. That puts it roughly 4% above its 200-day moving average of €36.22, confirming an uptrend in place since last year. Over twelve months, the shares have rallied 43%, yet they remain nearly 24% below the 52-week high of €49.93. The relative strength index stands at 55.8, indicating neither overbought nor oversold conditions — a neutral signal that leaves room for a move in either direction.

Beyond the courtroom and the trading floor, Bayer’s agricultural arm is also pressing ahead. At the Expoagro 2026 fair in Argentina, the company showcased its Preceon low-stature corn system, due to launch next year, and the PRO Carbono digital platform, which now connects around 3,000 producers focused on regenerative farming. These projects aim to strengthen Bayer’s position as farming margins come under pressure from regulatory scrutiny and commodity volatility.

The next major catalysts for the stock are the Supreme Court glyphosate ruling, expected by the end of June, and second-quarter earnings due on 4 August. Together, they will determine whether the recent sideways grind is a pause before a breakout or the start of a reversal. For now, Bayer’s shares are holding their ground — but the forces pulling at them are anything but quiet.